Clinical Trials Logo

Immunologic Suppression clinical trials

View clinical trials related to Immunologic Suppression.

Filter by:
  • None
  • Page 1

NCT ID: NCT05816538 Not yet recruiting - Breast Cancer Clinical Trials

The Immune Response of Breast Cancer Patients Treated With Levobupivacaine Using Paravertebral or Superficial Chest Blocks

Start date: April 2023
Phase: N/A
Study type: Interventional

The use of regional anesthesia in breast surgery improves the postoperative outcome, reduces the development of infection, and weakens the perioperative immunosuppressive response associated with the response to surgical stress. The investigators hypothesize that the use of propofol / paravertebral anesthesia and analgesia will be accompanied by a decrease in serum proinflammatory cytokines and/or an increase in anti-inflammatory cytokines compared to propofol / PECS 2 anesthesia and analgesia. The research will be on 100 respondents divided into two groups. 0.5% levobupivacaine will be administered to both groups. Serum concentrations of pro- and anti-inflammatory cytokines, and lymphocyte subpopulations 1h before, 24h, and 48h after surgery will be measured. The investigators aim to compare the effect of propofol / paravertebral and propofol / PECS 2 anesthesia and analgesia on serum perioperative values of pro-inflammatory and anti-inflammatory cytokines to standardize protocols and apply the best method of perioperative analgesia in breast cancer surgery.

NCT ID: NCT04448951 Recruiting - Sepsis Clinical Trials

Immune Homeostasis in Sepsis and Septic Shock

IMHOTEP
Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.

NCT ID: NCT03818334 Recruiting - Clinical trials for Graft Versus Host Disease

Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

Start date: November 6, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).